THERAPEUTIC AGENT FOR SARCOPENIA AND METABOLIC DISEASES
|Posted date||Mar 29, 2017|
|International application number||2016JP076627|
|International publication number||WO 2017043630|
|Date of international filing||Sep 9, 2016|
|Date of international publication||Mar 16, 2017|
|Title||THERAPEUTIC AGENT FOR SARCOPENIA AND METABOLIC DISEASES|
|Abstract||The present invention provides a therapeutic agent for sarcopenia or metabolic diseases, which contains a mu-crystalline (CRYM)-inhibiting substance as an active ingredient. The inhibiting substance is selected from the group consisting of an antisense nucleic acid for CRYM, an RNAi-induced nucleic acid, a ribozyme or an expression vector therefore, an antagonist antibody, and a low-molecular-weight compound capable of inhibiting the activity of CRYM.|
|Outline of related art and contending technology||
Is skeletal muscle, and maximal tissue in the body, accounts for 40-50% of body weight. Is skeletal muscle, a variety of physical activity in response to the stimulus, as well as muscle contraction and metabolism characteristics can be easily adapted to the size of a tissue of a highly plasticized. How the elasticity of the muscle to understand adjusted is, in the heart muscle biology and regenerative medicine is high and, muscular dystrophy, cancer cachexia and sarcopenia associated with aging such as failure of particular relevance to maintain muscle muscle disease (non-patent document 1, 2). The characteristics of the skeletal muscle, and having an anabolic or catabolic hormones and growth factors to be affected by. Thyroid hormones, normal development, cell proliferation and differentiation, heat production, controlling calcium homeostasis and physiological functions such as to have an important role in a wide range of (non-patent document 3-5). In skeletal muscle, thyroid hormone, speed muscle glycolysis plays an important role in the conversion of type (non-patent document 4,6-8).
Is mu crystallin (CRYM), was first discovered in kangaroo and lens, triiodothyronine (T3) from the cytoplasm to the nucleus of that regulate the transport NADPH dependent cytosolic triiodothyronine (T3) the characterization as binding proteins (non-patent document 9-11). Is CRYM, thyroid hormone receptor is a dimer comprising T3 to facilitate bonding and thyroid hormone action by a positive regulator, which in turn binds to its response element and the genome of the thyroid, thyroid hormone response genes in the nucleus to modulate the expression. However, mice deficient in CRYM, peripheral T3 to modify the action normally without exhibiting the growth of (non-patent document 12).
Muscular dystrophy (FSHD) is the upper shoulder face, an autosomal dominant disease, characterized by a unique pattern suffering from muscle, and particularly the facial skin and scapular band after lowering of the amount of muscle with muscle weakness of the lower extremities (non-patent document 13, 14). FSHD in muscle of the patient, an abnormally high expression has been reported CRYM while, in some other myopathies and muscular dystrophy, that are capable of up-regulation CRYM not observed (non-patent document 15). In another study, FSHD muscle myoblasts derived from highly expressed protein CRYM, CRYM FSHD DUX4 - related transcription factors directly induce expression is suggested (non-patent document 16). In addition, a method of diagnosing CRYM FSHD as a marker molecule is known (patent document 1).
|IPC(International Patent Classification)||
National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Contact Information for " THERAPEUTIC AGENT FOR SARCOPENIA AND METABOLIC DISEASES "
- Nagasaki University Intellectual Property Center
- URL: http://www.ipc.nagasaki-u.ac.jp/
- Address: 1-14 Bunkyo, Nagasaki City,Japan , 852-8521
- Phone: 81-95-819-2188
- Fax: 81-95-819-2189